Latest news
AbbVie’s Skyrizi retakes edge in pharma’s July ad spending league - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 13:45:00 GMTThe 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call - StockStoryStockStory · Fri, 07 Aug 2026 08:56:38 GMTThe 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call - The Chronicle-JournalThe Chronicle-Journal · Fri, 07 Aug 2026 05:47:00 GMTPrediction: AbbVie Will End The Year at This Price - 24/7 Wall St.24/7 Wall St. · Wed, 05 Aug 2026 14:00:26 GMTAbbVie's Next Catalyst Is Shifting From Skyrizi To Its Pipeline - FinimizeFinimize · Mon, 03 Aug 2026 20:04:21 GMTAbbVie: Skyrizi And Rinvoq Generate $8.03 Billion As Humira Revenue Falls 36% - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 03:49:28 GMTAbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 15:18:04 GMTAbbVie Has 2Q Beat Helped By Skyrizi and Rinvoq -- Market Talk - MoomooMoomoo · Fri, 31 Jul 2026 13:34:00 GMT